SOURCE: Paragon Financial Limited

Paragon Financial Limited

February 27, 2012 08:20 ET

Cancer Drug Market Evolves - Cannabis Science and ARIAD Pharmaceuticals Poised to Benefit

The Paragon Report Provides Equity Research on Cannabis Science & ARIAD Pharmaceuticals

NEW YORK, NY--(Marketwire - Feb 27, 2012) - Advances in cancer screening and treatment has caused the death rate from cancer to drop dramatically in recent years. Cancer death rates dropped by 1.8 percent per year in men and 1.6 percent per year in women between 2004 and 2008, according to the American Cancer Society's annual report on cancer statistics. The Paragon Report examines investing opportunities in the Healthcare sector and provides equity research on Cannabis Science Inc. (OTCBB: CBIS) & ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA). Access to the full company reports can be found at:

www.paragonreport.com/CBIS

www.paragonreport.com/ARIA

Death rates fell in all four of the most common cancers, lung, colon, breast and prostate, with lung cancer accounting for nearly 40 percent of the total drop in men and breast cancer account for 34 percent of the total decline in women, the American Cancer Society report finds.

The U.S. FDA has been approving cancer drugs at a faster rate than its European counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010, the FDA not only approved more new cancer drugs than did the EMA, it approved these drugs more quickly: of 23 drugs approved by both agencies, the median time from marketing submission to FDA approval was 182 days vs. EMA approval of 350 days according to the report.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Healthcare sector register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

ARIAD Pharmaceuticals' product pipeline includes Ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase (ALK) inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma.

Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. Earlier this month the company introduced a fourth cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer